The pan HLA DR-binding epitope improves adjuvant-assisted immunization with a recombinant protein containing a malaria vaccine candidate

Immunology Letters

Volumn 92, Issue 3, 2004, Pages 259-268

  Rosa, Daniela Santoro ^a   Tzelepis, Fanny ^a   Cunha, Maristela G ^a,b   Soares, Irene S ^c   Rodrigues, Mauricio M ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF PARÁ   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Pan HLA DR binding epitope; Recombinant vaccines and adjuvants

Indexed keywords

FREUND ADJUVANT; GLUTAMIC ACID DERIVATIVE; HLA DR ANTIGEN; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; PEPTIDE DERIVATIVE; PROLYLALANYLASPARTYLARGINYLGLUTAMIC ACID; PROTEIN P19; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY TITER; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CPG ISLAND; DRUG DESIGN; DRUG FORMULATION; DRUG SYNTHESIS; FEMALE; HLA SYSTEM; IMMUNE RESPONSE; IMMUNIZATION; LONGEVITY; MALARIA; MEROZOITE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING;

ANIMALS; CELL DIVISION; EPITOPES; HLA-DR ANTIGENS; HUMANS; IMMUNITY, CELLULAR; MALARIA VACCINES; MALARIA, FALCIPARUM; MICE; PLASMODIUM FALCIPARUM; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES;

EID: 1842680774     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2004.01.006     Document Type: Article

References (19)

1. Alexander J., Sidney J., Southwood S., Ruppert J., Oseroff C., Maewal A.et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity. 1:1994;751-761.
2. Franke E.D., Hoffman S.L., Sacci J.B. Jr., Wang R., Charoenvit Y., Appella E.et al. Pan DR binding sequence provides T-cell help for induction of protective antibodies against Plasmodium yoelii sporozoites. Vaccine. 17:1999;1201-1205.
3. Brossart P., Heinrich K.S., Stuhler G., Behnke L., Reichardt V.L., Stevanovic S.et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood. 93:1999;4309-4317.
4. Livingston B.D., Alexander J., Crimi C., Oseroff C., Celis E., Daly K.et al. Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J. Immunol. 162:1999;3088-3095.
5. Alexander J., del Guercio M.F., Maewal A., Qiao L., Fikes J., Chesnut R.W.et al. Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J. Immunol. 164:2000;1625-1633.
6. Ressing M.E., van Driel W.J., Brandt R.M., Kenter G.G., de Jong J.H., Bauknecht T.et al. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J. Immunother. 23:2000;255-266.
7. BenMohamed L., Krishnan R., Auge C., Primus J.F., Diamond D.J. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology. 106:2002;113-121.
8. La Rosa C., Wang Z., Brewer J.C., Lacey S.F., Villacres M.C., Sharan R.et al. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood. 100:2002;3681-3689.
9. Decroix N., Quan C.P., Pamonsinlapatham P., Bouvet J.P. Mucosal immunity induced by intramuscular administration of free peptides in-line with PADRE: IgA antibodies to the ELDKWA epitope of HIV gp41. Scand. J. Immunol. 56:2002;59-65.
10. Vichier-Guerre S., Lo-Man R., BenMohamed L., Deriaud E., Kovats S., Leclerc C.et al. Induction of carbohydrate-specific antibodies in HLA-DR transgenic mice by a synthetic glycopeptide: a potential anti cancer vaccine for human use. J. Pept. Res. 62:2003;117-124.
11. Singh M., O'Hagan D. Advances in vaccine adjuvants. Nat. Biotechnol. 17:1999;1075-1081.
12. Singh M., O'Hagan D.T. Recent advances in vaccine adjuvants. Pharm. Res. 19:2002;715-728.
13. 19 expressed in distinct bacterial vectors. Vaccine. 20:2001;385-396.
14. Rodrigues MH, Cunha MG, Machado RL, Ferreira OC Jr, Rodrigues MM, Soares IS. Serological detection of Plasmodium vivax malaria using recombinant proteins corresponding to the 19-kDa C-terminal region of the merozoite surface protein-1. Malar J 2003 [Epublication ahead of print].
15. Mac Donald R.A., Hosking C.S., Jones C.l. The measuremente of relative antibody affinity by ELISA using thiocyanate elution. J. Immunol. Methods. 106:1988;191-194.
16. Mendis K., Sina B.J., Marchesini P., Carter R. The neglected burden of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 64:2001;97-106.
17. Perera K.L.R.L., Handunnetti S.M., Holm I., Longacre S., Mendis K. Baculovirus merozoite surface protein 1 C-terminal recombinant antigens are highly protective in a natural primate model for human Plasmodium vivax malaria. Infect. Immun. 66:1998;1500-1506.
18. Stanisic D.I., Martin L.B., Liu X.Q., Jackson D., Cooper J., Good M.F. Analysis of immunological nonresponsiveness to the 19-kilodalton fragment of merozoite surface Protein 1 of Plasmodium yoelii: rescue by chemical conjugation to diphtheria toxoid (DT) and enhancement of immunogenicity by prior DT vaccination. Infect. Immun. 71:2003;5700-5713.
19. Caro-Aguilar I., Rodriguez A., Calvo-Calle J.M., Guzman F., De la Vega P., Patarroyo M.E.et al. Plasmodium vivax promiscuous T-helper epitopes defined and evaluated as linear peptide chimera immunogens. Infect. Immun. 70:2002;3479-3492.